Chardan Capital Begins Coverage on Clearside Biomedical (NASDAQ:CLSD)

Chardan Capital initiated coverage on shares of Clearside Biomedical (NASDAQ:CLSD) in a research report sent to investors on Wednesday, MarketBeat reports. The firm issued a buy rating and a $6.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Clearside Biomedical from a hold rating to a sell rating in a research note on Friday, May 10th. Needham & Company LLC restated a buy rating and issued a $4.00 price target on shares of Clearside Biomedical in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a buy rating and set a $5.00 price objective on shares of Clearside Biomedical in a research note on Tuesday, August 13th. Finally, Oppenheimer started coverage on shares of Clearside Biomedical in a research note on Tuesday, June 25th. They issued an outperform rating and a $5.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $4.83.

Clearside Biomedical Stock Up 1.0 %

Shares of CLSD opened at $1.02 on Wednesday. The company has a 50-day moving average price of $1.15 and a two-hundred day moving average price of $1.30. The stock has a market cap of $76.23 million, a price-to-earnings ratio of -1.85 and a beta of 2.43. Clearside Biomedical has a 12 month low of $0.65 and a 12 month high of $2.12.

Clearside Biomedical (NASDAQ:CLSD) last posted its earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter last year, the business earned ($0.15) EPS. Equities research analysts expect that Clearside Biomedical will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Clearside Biomedical

A number of large investors have recently modified their holdings of CLSD. International Assets Investment Management LLC bought a new stake in shares of Clearside Biomedical during the 1st quarter valued at $57,000. Vanguard Group Inc. increased its holdings in Clearside Biomedical by 14.5% in the first quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock valued at $3,811,000 after purchasing an additional 314,480 shares during the last quarter. SG Americas Securities LLC bought a new stake in Clearside Biomedical in the first quarter valued at about $49,000. Renaissance Technologies LLC lifted its stake in Clearside Biomedical by 6.6% in the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock valued at $757,000 after buying an additional 35,900 shares during the period. Finally, XTX Topco Ltd boosted its holdings in Clearside Biomedical by 172.2% during the second quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock worth $71,000 after buying an additional 34,359 shares during the last quarter. 18.75% of the stock is currently owned by institutional investors and hedge funds.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.